問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital

Division of Infectious Disease

Division of Thoracic Medicine

更新時間:2024-02-21

林奕宏
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

8Cases

2024-01-22 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Not yet recruiting7Sites

Recruiting7Sites

2023-08-31 - 2032-02-12

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2025-10-01 - 2027-10-01

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-08-01 - 2026-12-31

Phase II

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Recruiting5Sites

2025-06-16 - 2029-09-30

Phase III

Active
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITYR Study)
  • Condition/Disease

    Bronchiectasis

  • Test Drug

    BI 1291583 or matching placebo

Participate Sites
6Sites

Recruiting6Sites